Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review.

ABSTRACT:

Background

Patients with advanced pancreatic cancer have a poor prognosis and high burden of cancer-related symptoms. It is necessary to assess the trade-off of clinical benefits and possible harms of treatments with anticancer drugs (TAD). This systematic review aims to compare the effectiveness of TAD versus supportive care or no treatment, considering all patient-important outcomes.

Methods

We searched PubMed, Embase, Cochrane Library, and Epistemonikos. Two reviewers performed selection, data extraction and risk of bias assessment. We assessed certainty of the evidence using the GRADE approach.

Results

We included 14 randomised controlled trials. Chemotherapy may result in a slight increase in overall survival (MD: 2.97 months (95%CI 1.23, 4.70)) and fewer hospita

SUBMITTER: Salazar J 

PROVIDER: S-EPMC10422698 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature